

The RCPA grant was used to provide reagents to test the binding of large panel of novel antibodies, submitted to the HLDA10 workshop in Wollongong, to leukaemia cells from patients with Acute Myeloid Leukaemia. Seventeen of the antibodies tested bound to more than one of the AML samples. These included some antibodies to antigens which have previously been identified by other groups as potentially useful therapeutic targets e.g. Clec12A, IL-1RAC1, FLT3 and TIM-3. The other antibodies identified may also be potentially useful diagnostic or therapeutic tools. The work done in this workshop will help to predict their likely “on-target” toxicities by documenting their binding to healthy cell populations.

This work has now been published in the journal *Clinical & Translation Immunology* and has formed part of my PhD. I am now working as a clinical haematologist at Concord Hospital in Sydney, and continue to have an interest in immunology and novel therapies for AML.